Peng et al. reported that IGFBP-3 may contribute to androgen-induced antiproliferative effects in LNCaP human prostate cancer cells through increasing CDK1, P21, and P27, leading to G1 arrest30. The gene discussed is CDKN1B; the disease is prostate carcinoma.